脉冲场消融治疗心房颤动的安全性与有效性:MANIFEST-PF注册研究一年结局
MANIFEST-PF是一项回顾性、多国、患者水平注册研究,纳入2021年3月1日至2022年5月30日在24个欧洲中心接受多电极5分支脉冲场消融导管治疗房颤的1568例患者。中位随访367天,1年无房性心律失常Kaplan-Meier估计值为78.1%(95%CI 76.0%-80.0%),阵发性房颤优于持续性房颤(81.6% vs 71.5%,P=0.001),急性主要不良事件发生率1.9%。
要点
- 脉冲场消融术后1年无房性心律失常生存率为78.1%。
- 阵发性房颤疗效优于持续性房颤(81.6% vs 71.5%)。
- 急性主要不良事件发生率为1.9%。
核心结论
- 在获批后临床使用脉冲场消融技术治疗房颤的大型观察性注册研究中,导管消融在78%的房颤患者中具有临床有效性。
研究设计与样本
- MANIFEST-PF为回顾性、多国、患者水平注册研究,各中心患者前瞻性纳入各自注册库。
- 纳入2021年3月1日至2022年5月30日期间接受多电极5分支脉冲场消融导管治疗房颤的所有患者,共1568例,来自24个欧洲中心(77名术者)。
主要发现
- 患者年龄64.5±11.5岁,女性35%,阵发性/持续性房颤分别为65%/32%,CHA2DS2-VASc评分2.2±1.6,左心室射血分数中位数60%,左心房直径42 mm。
- 肺静脉隔离成功率为99.2%。
- 中位随访367天(四分位距289-421天),1年无房性心律失常Kaplan-Meier估计值为78.1%(95%CI 76.0%-80.0%)。
- 阵发性房颤患者临床有效性高于持续性房颤患者(81.6% vs 71.5%,P=0.001)。
- 急性主要不良事件发生率为1.9%。
关键数值与推荐
- 主要有效性终点为3个月空白期后基于心电图数据的临床记录房性心律失常(房颤/房扑/房速)≥30秒的无发生,无论是否使用抗心律失常药物。
- 安全性终点包括急性(术后<7天)和迟发(>7天)主要不良事件的复合终点。
临床怎么用
- 脉冲场消融可用于房颤的临床治疗,阵发性房颤患者可能获得更高的1年无房性心律失常率。
- 需关注急性主要不良事件,发生率约1.9%。
局限性
- 本研究为回顾性观察性注册研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care. METHODS: MANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (<7 days postprocedure) and latent (>7 days) major adverse events. RESULTS: At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA2DS2-VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289-421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%-80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P=0.001). Acute major adverse events occurred in 1.9% of patients. CONCLUSIONS: In this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF.
引用
- Turagam MK, Neuzil P, Schmidt B, et al. Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation. 2023. PMID: 37199171. doi:10.1161/CIRCULATIONAHA.123.064959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。